BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37310740)

  • 1. Analysis of Breast Cancer Family History, Estrogen Receptor Status, and Breast Cancer Outcomes in Sweden.
    Zhang Y; Wang QL; Zeng E; He W; Czene K
    JAMA Netw Open; 2023 Jun; 6(6):e2318053. PubMed ID: 37310740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Young-Onset Breast Cancer Outcomes by Time Since Recent Childbirth in Utah.
    Zhang Z; Bassale S; Jindal S; Fraser A; Guinto E; Anderson W; Mori M; Smith KR; Schedin P
    JAMA Netw Open; 2022 Oct; 5(10):e2236763. PubMed ID: 36239933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants.
    Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
    JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
    Zheng G; Sundquist J; Sundquist K; Ji J
    BMC Cancer; 2021 Nov; 21(1):1210. PubMed ID: 34772394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of estrogen receptor-specific breast cancer by family history of estrogen receptor subtypes and other cancers.
    Wang QL; Zhang Y; Zeng E; Grassmann F; He W; Czene K
    J Natl Cancer Inst; 2023 Sep; 115(9):1020-1028. PubMed ID: 37243749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neighborhood Disadvantage, African Genetic Ancestry, Cancer Subtype, and Mortality Among Breast Cancer Survivors.
    Iyer HS; Zeinomar N; Omilian AR; Perlstein M; Davis MB; Omene CO; Pawlish K; Demissie K; Hong CC; Yao S; Ambrosone CB; Bandera EV; Qin B
    JAMA Netw Open; 2023 Aug; 6(8):e2331295. PubMed ID: 37647068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
    Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
    JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
    Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
    Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer.
    Carleton N; Zou J; Fang Y; Koscumb SE; Shah OS; Chen F; Beriwal S; Diego EJ; Brufsky AM; Oesterreich S; Shapiro SD; Ferris R; Emens LA; Tseng G; Marroquin OC; Lee AV; McAuliffe PF
    JAMA Netw Open; 2021 Apr; 4(4):e216322. PubMed ID: 33856473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
    JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis.
    Marklund A; Lekberg T; Hedayati E; Liljegren A; Bergh J; Lundberg FE; Rodriguez-Wallberg KA
    JAMA Oncol; 2022 Oct; 8(10):1438-1446. PubMed ID: 36006625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status.
    Tutera AM; Sellers TA; Potter JD; Drinkard CR; Wiesner GL; Folsom AR
    Genet Epidemiol; 1996; 13(2):207-21. PubMed ID: 8722747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer.
    Mukama T; Kharazmi E; Xu X; Sundquist K; Sundquist J; Brenner H; Fallah M
    JAMA Oncol; 2020 Jan; 6(1):68-74. PubMed ID: 31725845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
    Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
    JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and prognostic analysis of double primary breast cancer and thyroid cancer].
    Zhai J; Kong XY; Fang Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1287-1291. PubMed ID: 34915638
    [No Abstract]   [Full Text] [Related]  

  • 20. Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
    Augustinsson A; Ellberg C; Kristoffersson U; Borg Å; Olsson H
    Acta Oncol; 2018 May; 57(5):595-603. PubMed ID: 29164969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.